Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- cholangiocarcinoma
- Source Database
- CIViC Evidence
- Description
- Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5905
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cholangiocarcinoma
- Evidence Direction
- Supports
- Drug
- Vemurafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26287849
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Sensitivity | true |